A clinical trial conducted in China showed single DNA biomarkers of SDC2, ADHFE1, and PPP2R5C had sensitivities of 81.9%, 81.9%, and 71.4%, and specificities of 99.0%, 90.0%, and 95.0% for CRC, respectively, and the sensitivities for precancerous lesions were 40.0%, 43.9%, and 54.0%, respectively. The gene discussed is ADHFE1; the disease is colorectal carcinoma.